Tetomilast.

Abstract

Otsuka is developing a once-daily oral formulation of the phosphodiesterase-4 inhibitor tetomilast for the potential treatment of ulcerative colitis (phase III) and chronic obstructive pulmonary disease (phase II).

• Authors: Seamus O'Mahony
• Journal: IDrugs : the investigational drugs journal (IDrugs) Vol. 8 Issue 6 Pg. 502-7 (Jun 2005) ISSN: 1369-7056 [Print] England
• PMID: 15906198 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Phosphodiesterase Inhibitors
• Thiazoles
• 3',5'-Cyclic-AMP Phosphodiesterases
• Cyclic Nucleotide Phosphodiesterases, Type 4
• tetomilast

Topics

• 3',5'-Cyclic-AMP Phosphodiesterases (drug effects)
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, chemical synthesis, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Colitis, Ulcerative (drug therapy)
• Contraindications
• Cyclic Nucleotide Phosphodiesterases, Type 4
• Humans
• Phosphodiesterase Inhibitors (adverse effects, chemical synthesis, pharmacology, therapeutic use)
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Structure-Activity Relationship
• Thiazoles (adverse effects, chemical synthesis, pharmacology, therapeutic use)